Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | GALR1 | P47211 | 1/20 | 0.38 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1636089 | 0.86 | ALDH1A1 (0.48) | MAPTTDP1MAPK1ALDH1A1KMT2A | |
| SCHEMBL1637052 | 0.82 | ATM (0.49) | MAPTTDP1MAPK1ALDH1A1L3MBTL1 | |
| SCHEMBL4354653 | 0.82 | MAPT (0.52) | MAPTTDP1MAPK1NSD2ALOX5 | |
| SCHEMBL1636978 | 0.81 | ACACB (0.41) | MAPTTDP1MAPK1ALDH1A1KMT2A | |
| SCHEMBL10411916 | 0.81 | MAPT (0.51) | MAPTTDP1MAPK1NSD2ALOX5 | |
| SCHEMBL1637036 | 0.78 | ALDH1A1 (0.36) | MAPTTDP1MAPK1ALDH1A1KMT2A | |
| SCHEMBL1636350 | 0.77 | TTR (0.40) | MAPTTDP1ALDH1A1KMT2AMEN1 | |
| SCHEMBL1635695 | 0.77 | ALDH1A1 (0.38) | MAPTMAPK1ALOX5ALDH1A1KMT2A | |
| SCHEMBL1637166 | 0.76 | SMN1; SMN2 (0.42) | MAPTTDP1ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL1635699 | 0.75 | HPGD (0.48) | MAPTTDP1ALDH1A1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2042506-B1 | SUBSTITUTED PHENYLETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX | UBE INDUSTRIES (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-7932398-B2 | Substituted phenylethynylgold-nitrogen-containing heterocyclic carbene complex | UBE INDUSTRIES, LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20090234130-A1 | SUBSTITUTED PHENYLETHYNYLGOLD-NITROGEN-CONTAINING HETEROCYCLIC CARBENE COMPLEX | UBE INDUSTRIES, LTD. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-2042506-A1 | SUBSTITUTED PHENYLETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX | Ube Industries, Ltd. (JP) | 2009-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234130-A1 | SUBSTITUTED PHENYLETHYNYLGOLD-NITROGEN-CONTAINING HETEROCYCLIC CARBENE COMPLEX | CCRL2, CCNL2, ATXN2L | MAPT 4610/4885TDP1 4727/4885MAPK1 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.